Scientist » Dr. Saravanabhavan Thangavel

Saravanabhavan Thangavel  


Genome editing Lab
Centre for Stem Cell Research
Christian Medical College

Office: +91 416 307-5136
Lab: +91 416 307-5135
Fax: +91 416 307-5103

Career Interests

Genome editing for Therapeutic applications

Haematopoietic stem cell expansion

Enhanced genome editing


  • 05/2011-02/2015 : Post Doctoral Scientist, Saint Louis University, Missouri, USA.
  • 07/2010-05/2011 : Post Doctoral Scientist, ICGEB, Italy.
  • 01/2007-06/2010 : PhD Molecular Biology, ICGEB, Italy.
  • 2004- 2006 : MSC Biotechnology, Bharathidasan University, TN, India.


  • DST-SERB Early career award.
  • ICGEB Post-doctoral award.


Our lab was started in September 2015 with a goal to develop gene and cell therapy for patients with genetic diseases. Our therapeutic approach is to precisely correct disease causing mutations at molecular level using cutting-edge genome editing technology CRISPR/Cas9. We are working to correct the genome of the patient’s hematopoietic stem cells ex vivo. Hematopoietic Stem Cell Gene therapy involves collection of HSCs from the patients, ex vivo correction for the deficient gene and transplantation back into the patients. The corrected HSCs in principle engraft and replenish the hematopoietic system curing the disease.

The current projects are mainly focused on:

  • Correcting hemoglobinopathies, in particular sickle-cell disease and β-thalassemia,
  • Correcting Primary Immuno deficiency disorder, in particular Wiskott-Aldrich Syndrome
  • Technology development for HSC genome editing

We are also actively looking at other potential opportunities to develop therapy for diseases where we believe genome editing will be beneficial. We select disease targets based on unmet medical needs of the country, advantages of genome editing over conventional medicines and phase at which our product can reach clinics.
Write us, if you would like to participate/know more about our work.


Research Fellows

Abisha Crystal

Abisha Crystal

Junior Research Fellow
Research Interests:

  • Genome editing
  • Gene Therapy for WAS
  • HSC manipulation
  • Education: MSc., Biotechnology

    Harish Kumar

    Harish Kumar

    Junior Research Fellow
    Research Interests:

  • Genome editing
  • Gene Therapy for SCD
  • Education:MSc., Biotechnology



    Selected Publications

    • Thangavel S, Berti M, Levikova M, Moore H, Gomathinayagam S, Vujanovic M, Pinto C, Lee E, Hendrickson E, Cejka P, Stewart S, Lopes M, Vindigni A. DNA2 drives processing and restart of reversed replication forks in human cells. Journal of Cell Biology 2015 Mar 2;208(5):545-62.
    • Li X, Lu X, Parvathaneni S, Bilke S, Zhang Y, Thangavel S, Vindigni A, Hara T, Zhu Y, Meltzer P, Lal A, Sharma S. Identification of RECQ1-regulated transcriptome uncovers a role of RECQ1 in regulation of cancer cell migration and invasion. Cell cycle journal 2014 Jun:16;13(15).
    • Berti M, Ray Chaudhuri A, Thangavel S, Gomathinayagam S. Kenig S, Vujanovic M, Odreman F, Glatter T, Graziano S, Mendoza-Maldonado R, Marino F, Lucic B, Biasin V, Gstaiger M, Aebersold R, Sidorova JM, Monnat RJ Jr, Lopes M, Vindigni A. Human RECQ1 promotes restart of replication forks reversed by DNA topoisomerse I inhibition. Nature Structural and Molecular Biology 2013 Mar; 20(3): 347-54.
    • Xu. D., Muniandy P, Agama K, Yin J, Thangavel S, Shen X, Ii M, Guo R, Fox D, Meetei R, Wilson L, Nguyen H, Stark M. J, Weng N, Brill S, Li.L, Vindigni A, Pommier Y, Seidman M, and Wang W. Rif1 provides a new DNA-binding interface for the Bloom syndrome complex to maintain normal replication. EMBO J. 2010. Sep: 29(18): 3140-55.
    • Thangavel S, Mendoza M.R.,Tissino E, Sidorova M.J, Yin J, Wang W, Monnat J.R, Falaschi A and Vindigni A. Human RECQ1 and RECQ4 Helicases Play Distinct Roles in DNA Replication Initiation. Molecular and Cellular Biology. 2010 Mar; 30(6): 1382-96.

    "Contents will be updated soon."

    "Contents will be updated soon."

    • Dr. R.V. Shaji
    • - Gene therapy for SCD
      - Gene therapy for WAS
    • Dr. Mohan Kumar. KM
    • - SCD gene therapy
    • Dr. Srujan Kumar
    • - Nano carriers for delivering genome editing tools
    • Dr. Alok Srivastava
    • - Gene therapy for SCD
      - Gene therapy for WAS